BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7732895)

  • 1. ABT-299, a potent antagonist of platelet activating factor.
    Summers JB; Albert DH; Davidsen SK; Conway RG; Holms JH; Magoc TJ; Luo G; Tapang P; Rhein DA; Carter GW
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():475-7. PubMed ID: 7732895
    [No Abstract]   [Full Text] [Related]  

  • 2. Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist.
    Kruse-Elliott KT; Albert DH; Summers JB; Carter GW; Zimmerman JJ; Grossman JE
    Shock; 1996 Apr; 5(4):265-73. PubMed ID: 8721386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.
    Albert DH; Conway RG; Magoc TJ; Tapang P; Rhein DA; Luo G; Holms JH; Davidsen SK; Summers JB; Carter GW
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1595-606. PubMed ID: 8667228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.
    Albert DH; Magoc TJ; Tapang P; Luo G; Morgan DW; Curtin M; Sheppard GS; Xu L; Heyman HR; Davidsen SK; Summers JB; Carter GW
    Eur J Pharmacol; 1997 Apr; 325(1):69-80. PubMed ID: 9151941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist.
    Albert DH; Magoc TJ; Menacherry SD; Morgan DW; Sun E; Reyes AE; Kleinert HD; Carter GW; Summers JB
    Inflamm Res; 1997 Jul; 46(7):272-7. PubMed ID: 9266276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of platelet-activating factor-receptor antagonism on endotoxin-induced lung dysfunction in sheep.
    Snapper JR; Lu W; Lefferts PL; Thabes JS
    J Appl Physiol (1985); 1998 May; 84(5):1610-4. PubMed ID: 9572806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist.
    Albert DH; Magoc TJ; Kleinert HD; Sun E; Reyes AE; Carter GW; Summers JB
    Adv Exp Med Biol; 1996; 416():381-7. PubMed ID: 9131177
    [No Abstract]   [Full Text] [Related]  

  • 9. Beneficial effects of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate, a specific PAF antagonist, in endotoxin and anaphylactic shock.
    Terashita Z; Imura Y; Nishikawa K; Sumida S
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():715-7. PubMed ID: 3004156
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-activating factor antagonists: scientific background and possible clinical applications.
    Koltai M; Guinot P; Hosford D; Braquet PG
    Adv Pharmacol; 1994; 28():81-167. PubMed ID: 8080821
    [No Abstract]   [Full Text] [Related]  

  • 13. N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist.
    Davidsen SK; Summers JB; Albert DH; Holms JH; Heyman HR; Magoc TJ; Conway RG; Rhein DA; Carter GW
    J Med Chem; 1994 Dec; 37(26):4423-9. PubMed ID: 7799395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the physicochemical properties of the micelles by the novel platelet activating factor receptor antagonist E5880.
    Asai Y; Watanabe S
    Eur J Pharm Biopharm; 2000 May; 49(3):219-23. PubMed ID: 10799812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
    Albert DH; Luo G; Magoc TJ; Tapang P; Holms JH; Davidsen SK; Summers JB; Carter GW
    Shock; 1996 Aug; 6(2):112-7. PubMed ID: 8856845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activating factor mediates systemic circulatory collapse after temporary hepatic inflow occlusion.
    Fukuoka T; Nakajima Y; Horikawa M; Aomatsu Y; Yoshimura A; Ueno M; Ko S; Nakano H
    Transplant Proc; 1993 Apr; 25(2):1809-10. PubMed ID: 8470175
    [No Abstract]   [Full Text] [Related]  

  • 18. Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists.
    Houlihan WJ; Cheon SH; Parrino VA; Handley DA; Larson DA
    J Med Chem; 1993 Oct; 36(21):3098-102. PubMed ID: 8230095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation.
    Bastos da Silva M; Delaunois A; Gustin P; Godeau JM; Lekeux P
    Vet Res; 2000; 31(2):267-72. PubMed ID: 10779205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes.
    Marquis O; Robaut C; Cavero I
    J Pharmacol Exp Ther; 1988 Feb; 244(2):709-15. PubMed ID: 2831350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.